title: [Anti-osteoporotic drugs and their interactions with multiple organs].
abstract: Anti-osteoporotic drugs directly control bone metabolism. Then, they are possibly involved in interactions between bone and many other tissues. It is not, however, clear how they influence several organs other than bone, or what clinical significance they have. Recently, accumulating evidence suggests that osteocalcin as a humoral factor from bone is actively involved in glucose metabolism. Since interaction between osteoporosis and diabetes mellitus is an emerging clinical issue, there are several clinical questions under vigorous investigations.
authors.affiliation: Endocrine Center, Toranomon Hospital, Tokyo, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Takeuchi
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002762:Cholecalciferol / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000503:physiopathology* / Q000517:prevention & control; D053245:RANK Ligand / Q000276:immunology
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D002762:Cholecalciferol